倍他乐克联合通心络胶囊治疗冠心病心绞痛的临床效果

薛向春，汪玉梅

（陕西省绥德县医院，陕西 榆林，718000）

浏览次数：195次 下载次数：286次

摘要：

目的 系统评价倍他乐克联合通心络胶囊治疗冠心病心绞痛的临床效果。方法 选择我院收治的冠心病心绞痛患者96例，随机分为研究组和对照组，各48例。对照组患者在常规治疗的基础上给予倍他乐克治疗，研究组患者在对照组基础上联合使用通心络胶囊治疗，观察两组患者的临床疗效。结果 研究组患者临床总有效率为95.83%（46/48），明显高于对照组的 83.33%（40/48）（P<0.05）；治疗前，两组TG、TC、HDL、LDL水平比较，差异无统计学意义（P>0.05）；治疗后，两组TG、TC、LDL均降低，HDL升高，且研究组TG、TC、LDL水平低于对照组，HDL水平高于对照组，差异有统计学意义（P<0.05）。两组不良反应发 生率比较，差异不显著（P>0.05）。结论 倍他乐克联合通心络胶囊治疗冠心病心绞痛患者临床效果显著，不良反应少，安全性高。

关键词：冠心病心绞痛；倍他乐克；通心络胶囊

中图分类号：R541.4文献标志码：A文章编号：2096-1413(2017)16-0026-02

Clinical effect of betaloc combined with Tongxinluo capsule in treatment of angina pectoris of coronary heart disease
XUE Xiang-chun, WANG Yu-mei
(Suide County Hospital of Shaanxi Province, Yulin 718000, China)

ABSTRACT: Objective To evaluate the clinical effect of betaloc combined with tongxinluo capsule in treating angina pectoris of coronary heart disease. Methods Ninety-six patients with angina pectoris of coronary heart disease treated in our hospital were selected and randomly divided into study group and control group, with 48 cases in each group. The control group received betaloc on the basis of the routine treatment, while the study group received Tongxinluo capsule on the basis of the control group, the clinical efficacy of the two groups were observed. Results The clinical total effective rate of the study group was 95.83% (46/48), which was significantly higher than 83.33% (40/48) of the control group (P<0.05). Before treatment, there was no significant difference on the levels of TG, TC, HDL and LDL between the two groups (P>0.05); after treatment, the levels of TG, TC and LDL in the two groups were lower, and HDL was higher than those before treatment, and the levels of TG, TC and LDL in the study group were lower and HDL was higher than those in the control group (P<0.05). There was no significant difference on the incidence rate of adverse reactions between the two groups (P>0.05). Conclusion Betaloc combined with Tongxinluo capsule in the treatment of angina pectoris of coronary heart disease has obvious clinical effect, with less adverse reactions and high security.
KEYWORDS: angina pectoris; betaloc; Tongxinluo capsule

参考文献:
[1] 袭杰.倍他乐克联合通心络胶囊治疗冠心病心绞痛疗效分析[J].中国实用医药,2015,10(34):189-190.
[2] 姜海东,由丽娜,马秋野.倍他乐克联合通心络胶囊治疗冠心病心绞痛临床研究[J].安徽医药,2013,17(8):1392-1393.
[3] 李东.倍他乐克与通心络联合治疗冠心病心绞痛的疗效[J].宜春学院学报,2014,36(9):77-78.
[4] 王三合,王治伦.曲美他嗪联合通心络胶囊治疗冠心病心绞痛疗效观察[J].陕西中医,2016,37(2):169-170.
[5] 孙春霞,孙善卫,袁丽娜.冠心病心绞痛患者经倍他乐克联合通心络治疗的临床效果观察[J].世界中医药,2015,10(A1):577.
[6] 郭雨青,甄毅锋,石雁.通心络胶囊联合他汀类药物治疗冠心病心绞痛疗效观察[J].现代中西医结合杂志,2016,25(10):1115-1117.
[7] 张淑娟,赵庆彦,代子玄,等.参松养心胶囊联合通心络胶囊治疗冠心病合并室性早搏疗效及安全性的系统评价[J].中国心血管病研究,2015,13(10):878-881.
[8] 崔春便,程华.通心络联合氯吡格雷对不稳定型心绞痛患者血管内皮功能和炎性因子的影响[J].疑难病杂志,2014,12(9):936-938.